Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the
adoption of AI to advance precision medicine and patient care,
today announced the collaboration with Flatiron Health, a leading
healthtech company dedicated to expanding the possibilities of
point of care solutions in oncology, to integrate its comprehensive
genomic testing directly into Flatiron’s cloud-based Electronic
Medical Record (EMR) platform, OncoEMR® through the Molecular
Profiling Integration (MPI). This integration will provide
oncologists with seamless access to Tempus’ suite of testing
options, enhancing their ability to deliver personalized cancer
care.
Flatiron’s MPI—a two-way integration between laboratories and
OncoEMR—will allow the 4,200 providers at more than 800
community-based cancer care locations across the U.S. in Flatiron’s
network to order and receive results from Tempus directly in the
OncoEMR workflow. The integration will enable electronic ordering,
order tracking, and the receipt of Tempus test results directly
within the OncoEMR platform, significantly reducing administrative
burden and improving the experience for care providers.
“This collaboration represents a significant step forward in the
integration of Tempus’ molecular profiling capabilities into
everyday oncology practice,” said Ezra Cohen, MD, Chief Medical
Officer of Oncology at Tempus. “By leveraging Flatiron’s Molecular
Profiling Integration within OncoEMR, we are enabling oncologists
to access our comprehensive genomic tests with greater efficiency
and precision, ultimately enhancing patient care and outcomes.”
“Integrating Tempus' suite of testing options into OncoEMR marks
a step forward in personalizing cancer care, enabling more precise
diagnoses and tailored treatments for every person with cancer,”
said Stephen Speicher, MD, Senior Medical Director, Head of
Clinical Oncology and Safety at Flatiron. “This collaboration
ensures oncologists across the Flatiron network have convenient
access to the information needed to practice precision medicine,
improve patient outcomes, and spend more meaningful time with their
patients, ultimately enhancing the care experience for both
providers and those they serve.”
A key feature of this integration includes unified ordering in
which a single order form will be deployed across all
MPI-participating practices, streamlining the process and ensuring
consistency. Also, this integration will give providers
comprehensive access to Tempus tests, including xT, xR, xF/xF+,
xG/xG+ Ambry, xM/xM (NeXT Personal® Dx), as well as several
AI-enabled, algorithmic, add-on tests.
About Tempus
Tempus is a technology company advancing precision medicine
through the practical application of artificial intelligence in
healthcare. With one of the world’s largest libraries of multimodal
data, and an operating system to make that data accessible and
useful, Tempus provides AI-enabled precision medicine solutions to
physicians to deliver personalized patient care and in parallel
facilitates discovery, development and delivery of optimal
therapeutics. The goal is for each patient to benefit from the
treatment of others who came before by providing physicians with
tools that learn as the company gathers more data. For more
information, visit tempus.com.
About Flatiron Health
Flatiron Health is a healthtech company expanding the
possibilities for point of care solutions in oncology and using
data for good to power smarter care for every person with cancer.
Through machine learning and AI, real-world evidence, and
breakthroughs in clinical trials, we continue to transform
patients’ real-life experiences into knowledge and create a more
modern, connected oncology ecosystem. Flatiron Health is an
independent affiliate of the Roche Group.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended (the “Securities Act”), and Section 21E of the Securities
Exchange Act of 1934, as amended, about Tempus and Tempus’ industry
that involve substantial risks and uncertainties. All statements
other than statements of historical facts contained in this press
release are forward-looking statements, including, but not limited
to, statements regarding Tempus’ interoperability initiatives,
integrations with electronic health record platforms, and efforts
to reduce administrative burden associated with test ordering and
results. In some cases, you can identify forward-looking statements
because they contain words such as “anticipate,” “believe,”
“contemplate,” “continue,” “could,” “estimate,” “expect,” “going
to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,”
“should,” “target,” “will,” or “would” or the negative of these
words or other similar terms or expressions. Tempus cautions you
that the foregoing may not include all of the forward-looking
statements made in this press release.
You should not rely on forward-looking statements as predictions
of future events. Tempus has based the forward-looking statements
contained in this press release primarily on its current
expectations and projections about future events and trends that it
believes may affect Tempus’ business, financial condition, results
of operations and prospects. These forward-looking statements are
subject to risks and uncertainties related to: Tempus’ financial
performance; the ability to attract and retain customers and
partners; managing Tempus’ growth and future expenses; competition
and new market entrants; compliance with new laws, regulations and
executive actions, including any evolving regulations in the
artificial intelligence space; the ability to maintain, protect and
enhance Tempus’ intellectual property; the ability to attract and
retain qualified team members and key personnel; the ability to
repay or refinance outstanding debt, or to access additional
financing; future acquisitions, divestitures or investments; the
potential adverse impact of climate change, natural disasters,
health epidemics, macroeconomic conditions, and war or other armed
conflict, as well as risks, uncertainties, and other factors
described in the section titled “Risk Factors” in Tempus’ Quarterly
Report on Form 10-Q for the quarter ended September 30, 2024 filed
with the Securities and Exchange Commission (“SEC”) as well as in
other filings Tempus may make with the SEC in the future. In
addition, any forward-looking statements contained in this press
release are based on assumptions that Tempus believes to be
reasonable as of this date. Tempus undertakes no obligation to
update any forward-looking statements to reflect events or
circumstances after the date of this press release or to reflect
new information or the occurrence of unanticipated events, except
as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241112753574/en/
Tempus Communications Erin Carron media@tempus.com
Flatiron Health Nina Toor press@flatiron.com
Tempus AI (NASDAQ:TEM)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
Tempus AI (NASDAQ:TEM)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024
